Caladrius Biosciences, Bellerophon Therapeutics, Celsion, Albireo Pharma and Trillium Therapeutics were last week’s top gainers on the NASDAQ Biotechnology Index.
Last week, the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) dipped by 0.48 percent from Monday’s (June 18) high of 3,547.13 points to settle in at 3,530.09 points as of 1:37 p.m. EST on Friday (June 22).
Some of the big news during last week’s trading period included Myriad Genetics (NASDAQ:MYGN) receiving supplementary premarket approval for its BRACAnalysis CDx, which was announced on Monday. Neovasc (NASDAQ:NVCN) also had a big week with its Neovasc Reducer implanted in the first US patient, while Inovio Pharmaceuticals (NASDAQ:INO) dosed its first patient in its Phase 1/2 immuno-oncology trial for newly diagnosed glioblastoma (GBM) patients.
A number of other biotech and pharma stocks also had big weeks in terms of rising share prices, including:
- Caladrius Biosciences (NASDAQ:CLBS)
- Bellerophon Therapeutics (NASDAQ:BLPH)
- Celsion (NASDAQ:CLSN)
- Albireo Pharma (NASDAQ:ALBO)
- Trillium Therapeutics (NASDAQ:TRIL)
Here’s a closer look at those companies.
First on last week’s top weekly NASDAQ biotech stocks list is Caladrius Biosciences. Caladrius is a clinical stage development company with a number of cell therapy products in its pipeline.
The company is currently investigating its lead product candit, CLBS03, which is an ex vivo expanded polyclonal T regulatory cell therpay to reat recent-onset type 1 diabetes. The product is enrolling a Phase 2 trial.
Caladrius Biosciences announced on Tuesday (June 19) it had received FDA regenerative medicine advanced therapy designation for its late stage CD34+ cell therapy program to treat refractory angina. The news pushed the company’s share price up significantly over the five-day period by 76.54 percent to reach US$7.15 as of 2:17 p.m. EST on Friday.
Next is Bellerphon Therapeutics is a clinical stage biotherapeutics company with a focus on developing products for treating cardiopulmonary diseases.
The company’s INOpulse programs are evaluating the treatment of pulmonary aterial hypertension, pulmonary hyperentension associated with chronic obstructive pulmonary disease, and pulmonary hypertension associated with interstitial lung disease.
That being said, Bellerophon Therapeutics didn’t have any news during last week’s trading period to describe its rising share price, although the increase is still worth nothing. Over the week shares of the company rose 19.67 percent to reach US$2.92 as of 2:25 p.m. EST on Friday.
Middle of the pack on last week’s five top weekly NASDAQ biotech stocks list is Celsion, a biopharmaceutical company focused on cancer treatments including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies.
The company’s lead product candidate is ThermoDox, which is a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in Phase 3 trial combined with RFA to treat hepatocellular carcinoma. Celsion also has in its pipeline GEN-1, a DNA-mediated immunotherapy for localized treatment of ovarian cancer.
However, Celsion didn’t have any news last week that could relate to its share price spike, which rose 16.29 percent to US$3.25 as of 2:34 p.m. EST on Friday.
Next is Albireo Pharma, a clinical stage biopharmaceutical company with a focus on developing and commercialization of novel bile modulators to treat orphan pediatric liver diseases as well as other liver gastrointestinal diseases and disorders.
The company announced on Monday that it had appointed Jason G. Duncan as general counsel and secretary, although that may not have contributed to its rising share price. The week previous Albireo had received rare pediatric disease designation to its A4250 from the US Food and Drug Administration (FDA).
Over last week’s trading period shares of Albireo Pharma increased 11.31 percent to settle in at US$35.79 as of 2:40 p.m. EST on Friday.
Rounding out last week’s five top weekly NASDAQ biotech stocks list is Trillium Therapeutics, an immuno-oncology company with a focus on developing novel cancer therapies.
Trillium’s lead product, TTI-621, is a SIRPaFc fusion that contains CD47-binding domain of a human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). it is designed to act as a soluble decoy receptor to prevent CD47 from delivering its inhibitory signal.
The company announced on Tuesday that it had entered into a sales agreement with Cowan and Company LLC and that it had also filed a prospectus supplement, which may have contributed to its rising share price. Over the week shares of Trillium increased 9.84 percent to reach US$3.13 as of 2:45 p.m. EST on Friday.
Don’t forget to follow us at @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Biotech Stocks articles is retrieved each Friday at 10:00 a.m. PST using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $50 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.